

October 19, 2026

Company Name: Veritas In Silico Inc.

Representative: Shingo NAKAMURA,

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact: Tsuneo GODA,

Executive Officer & General Manager,

Corporate Planning Division

Email: ir@veritasinsilico.com

Notice Concerning the Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.

Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Shingo NAKAMURA, hereinafter referred to as "the Company") hereby announces that it has achieved a key research milestone — specifically, the identification of hit compounds — under the joint drug discovery research agreement signed on July 28, 2021, with Toray Industries, Inc. (Headquarters: Chuo-ku, Tokyo; President: Mitsuo Ohya; hereinafter referred to as “Toray”).

This joint research aims to create innovative small-molecule drugs targeting messenger RNA (mRNA).

● Overview of the Joint Drug Discovery Research

Under this joint drug discovery research, the Company leverages its proprietary AI-driven drug discovery platform, aibVIS, aiming to create innovative small-molecule drugs targeting the mRNA of the PCSK9 gene, which Toray selected as the primary drug target.

PCSK9 is a gene encoding a protein involved in lipid metabolism. Under this joint research, the Company and Toray are jointly promoting research activities from identifying target structures on PCSK9 mRNA to obtaining compounds that act on these structures and demonstrate therapeutic efficacy.

The Company contributes various technologies to this joint research, including RNA structure analysis, screening for RNA-binding compounds, RNA sub-structure measurement, 3D structural analysis, and molecular design.

● About PCSK9

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a protein mainly produced in the liver that plays a critical role in regulating plasma LDL cholesterol levels. Because PCSK9 promotes the degradation of LDL receptors located on the surface of liver cells—which are responsible for taking up circulating LDL cholesterol — inhibiting PCSK9 function can reduce in plasma LDL cholesterol levels.

PCSK9 is an important drug target for dyslipidemia and atherosclerotic cardiovascular disease, and several drugs targeting PCSK9 have already been commercialized. Thus, PCSK9 is a clinically validated therapeutic target. Meanwhile, small-molecule drugs generally possess characteristics suitable for reaching

a broad patient population in terms of manufacturing and supply, offering the potential to deliver PCSK9-targeted therapies to more patients than ever before.

In this joint drug discovery research, rather than targeting the PCSK9 protein itself, the approach targets the specific three-dimensional structure formed by PCSK9 mRNA — the genetic template for the protein — using small-molecule compounds. If successful, this novel approach will demonstrate the utility of small-molecule drug discovery targeting mRNA three-dimensional structures and potentially add new therapeutic options to PCSK9-targeted treatments.

The global PCSK9 inhibitor market is forecast to reach approximately USD 14 billion by 2034 (“PCSK9 Inhibitor Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025–2034”). Creating a PCSK9-targeted drug with a novel mechanism of action could potentially capture a share of this market.

● Impact on Financial Condition and Business Performance

As no milestone payments or immediate milestone-related income will be generated as a direct result of achieving this milestone, there are no revisions to the financial forecasts for the fiscal year ending December 2026, which were previously announced on February 12, 2026.

Intellectual property and proprietary rights resulting from the achievements of this joint drug discovery research shall be shared with Toray. As research, development, and eventual commercialization progress, the Company anticipates these advancements will meaningfully contribute to the medium- to long-term enhancement of its corporate value.

In case any material matters requiring disclosure arise in the future, it will be promptly disclosed.

END

For Further Information, Contact:

- Veritas In Silico Website Inquiry Form : <https://www.veritasinsilico.com/en/contact/>